Skip to main content

Table 1 Clinical features of HUS in children in Norway, 1999-2008

From: Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999–2008

Clinical feature Diarrhoea-associated HUS (N = 38) Non-diarrhea-associated HUS (N = 9)
Time first symptom to admittance (median, days) 6 (4–9) 5 (2–10)
Age at admittance (median, months/years)a 31 (range; 5 months–15 years)a 18 (range; 7 months–6 years)a
Duration of initial hospitalization (median, days) 15 (11–24) 16 (8–42)
Duration of total time hospitalizedb (median, days) 18 (12–24) 16 (8–53)
Prodromal diarrhea (n, %) 37 (97 %) 2 (22 %)
Prodromal bloody diarrhea (n, %) 27 (71 %) 2 (22 %)
Hypertension at admittance (n, %) 4 (24 %) (N = 17) 2 (33 %) (N = 6)
Hypertension registered during admittance (n, %) 30 (83 %) (N = 36) 8 (100 %) (N = 8)
Oligoanuria (n, %) 29 (76 %) 5 (56 %)
Death acute phase (n, %) 2 (5 %) 0 (0 %)
Non-renal complications
Neurological complications (n, %) 9 (24 %) 2 (22 %)
Cardiac complications (n, %) 2 (5 %) 0 (0 %)
Respiratory complications (n, %) 10 (26 %) 2 (22 %)
Gastrointestinal complications (n, %) 5 (13 %) 1 (11 %)
Sepsis (n, %) 11 (29 %) 3 (33 %)
Renal outcome
Proteinuria at first follow-up (n, %) 16 (50 %) (N = 32) 7 (78 %)
Proteinuria ≥ 1 year after initial admission (n, %) 8 (38 %) (N = 21) 4 (57 %) (N = 7)
Hypertension at first follow-up (n, %) 10 (31 %) (N = 32) 5 (56 %)
Hypertension ≥ 1 year after initial admission (n, %) 5 (26 %) (N = 19) 4 (80 %) (N = 5)
Chronic kidney disease (n, %) 2 (5 %) 1 (11 %)
End-stage renal disease (ESRD) 1 (3 %) 0 (0 %)
  1. Results are presented as number of cases, n (%) and median (interquartile range). If data on the feature was not available in all medical records, the number of cases where available is presented (N = number of cases where available). HUS hemolytic uremic syndrome
  2. aRange; smallest and highest value for illustrational purposes
  3. bTime hospitalized including all readmissions for complications and extensive (not regular) follow-up